Amgen Inc.

NASDAQ:AMGN

Drug Manufacturers - General

Healthcare
$443.89 -2.03%

-$6.93 today

Market cap
$240.11B
Beta
0.42
P/E (TTM)
23.2
EPS (TTM)
$14.44
Dividend yield
2.93%
52W Low $267.83High $391.29

Volume 2.58M

Average 2.76M

AMGN Long-term Investments

Investments the company intends to hold for more than a year.

Amgen Inc.NASDAQ: AMGN

Long-term Investments · Q2 FY2026 · quarter ended Jun 2026

Long-term investments remains negative

Q2 FY2026 long-term investments was $0, compared with $4.94B a year earlier.

Context

  • Long-term investments amounted to 0.0% of total assets at the end of Q2 FY2026, down 5.6 pp from a year earlier.
  • Long-term investments increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term investments keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$6.8B+27.1% YoY
Year agoJun 2025
$4.94B-100.0% since
Long-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+27.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Investments history

USD · from the balance sheet

Latest · FY2025
6.8B USD
Year-over-year change
+27.1%

Long-term Investments vs competitors

How AMGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term investments is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -100.0% is the lowest of 9, against a peer median of +15.0%.
  • Long-term investments amounts to 0.0% of total assets for AMGN, versus a peer median of 0.9%.
AMGN Competitors
Long-term Investments for AMGN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AZNAstraZeneca PLCSep 2026$4.67B USD+104.2%—3.9%
LLYEli Lilly and CompanyJun 2026$3.86B USD+20.2%-1.2%2.7%
NVSNovartis AGJun 2026$2.37B USD+9.7%+12.8%1.9%
PFEPfizer Inc.Jun 2026$1.56B USD+596.0%-51.3%0.8%
MRKMerck & Co., Inc.Jun 2026$1.22B USD+57.9%+30.2%0.9%
GSKGSK plcJun 2026£966.13M GBP-27.8%—1.6%
BMYBristol-Myers Squibb CompanyJun 2026$397M USD-82.4%+4.7%0.5%
ABBVAbbVie Inc.Jun 2026$266M USD-14.2%+7.5%0.2%
AMGNAmgen Inc.Jun 2026$0 USD-100.0%—0.0%
JNJJohnson & JohnsonSep 2026$0 USD——0.0%
Peer median (excluding AMGN) —+15.0%+6.1%0.9%

Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents7.99B7.63B10.94B11.97B9.13B
Short-term Investments48M1.68B000
Net Receivables5.84B6.39B7.94B7.5B9.57B
Inventory4.09B4.93B9.52B7B6.23B
Other Current Assets200M355M281M419M4.13B
Total Current Assets19.39B22.19B30.33B29.03B29.06B
Property, Plant & Equipment (Net)5.18B5.43B5.94B6.54B8.52B
Goodwill14.89B15.53B18.63B18.64B18.68B
Intangible Assets15.18B16.08B32.64B27.7B22.28B
Long-term Investments004.71B5.36B6.8B
Tax Assets00000
Other Non-current Assets6.52B5.9B4.9B4.58B5.25B
Total Non-current Assets41.78B42.94B66.82B62.81B61.53B
Total Assets61.17B65.12B97.15B91.84B90.59B
Account Payables1.37B1.57B1.59B1.91B2.37B
Short-term Debt87M1.59B1.44B3.55B4.6B
Tax Payables701M1.2B1.66B00
Deferred Revenue00000
Other Current Liabilities1.62B1.1B1.38B1.33B1.44B
Total Current Liabilities12.18B15.69B18.39B23.1B25.49B
Long-term Debt33.22B37.35B63.17B56.55B50.01B
Deferred Tax Liabilities011M2.35B1.62B1.37B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities9.06B8.41B7.01B4.7B5.07B
Total Non-current Liabilities42.28B45.77B72.53B62.86B56.44B
Total Liabilities54.47B61.46B90.92B85.96B81.93B
Common Stock32.1B32.51B33.07B33.53B34.02B
Retained Earnings(24.6B)(28.62B)(26.55B)(27.59B)(25.11B)
Accumulated OCI(796M)(231M)(289M)(66M)(258M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity6.7B3.66B6.23B5.88B8.66B
Total Debt33.31B38.95B64.61B60.1B54.6B
Net Debt25.32B31.32B53.67B48.13B45.48B

Amgen Inc.

NASDAQ:AMGN

Intrinsic Alpha fair value

Locked

Current Price

$443.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.